The Effect of Metformin on Adipokines Levels: A Systematic Review and Meta-Analysis of Randomized-Controlled Trials Publisher Pubmed



Zhao D¹ ; Sohouli MH^{2, 3} ; Rohani P³ ; Fotros D⁴ ; Velu P⁵ ; Ziamanesh F³ ; Fatahi S⁴ ; Shojaie S³ ; Li Y¹ Show Affiliations
Source: Diabetes Research and Clinical Practice Published:2024

Abstract

Background: Considering the role of adipokine on diseases related to metabolic syndrome and even chronic diseases, it seems necessary to investigate effective interventions on these factors. This study aimed to comprehensively investigate the effects of metformin on adipokines. Methods: A comprehensive search was conducted in five databases using established keywords. The purpose of this search was to uncover controlled studies that have examined the impact of metformin on adipokines, specifically leptin, adiponectin, and resistin. The random-effects model analysis was used to provide pooled weighted mean difference and 95% confidence intervals. Results: Forty-nine studies were included in this article. The pooled findings showed that that the administration of metformin significantly decreases leptin (WMD: −3.06 ng/ml, 95 % CI: −3.81, −2.30, P < 0.001) and resistin (WMD: −1.27 µg/mL, 95 % CI: −2.22, −0.31, P = 0.009) levels in different populations compared to the control group. However, no significant effect of this antidiabetic drug on adiponectin levels was reported. The results obtained from the subgroup results in the present study also showed that metformin in people with a BMI greater than 30 kg/m2 compared to a BMI ≤ 30 kg/m2 causes a significant decrease in leptin levels and an increase in adiponectin levels. Also, metformin in lower doses (≤1500 mg/day) and younger people (<30 years) causes a significant increase in adiponectin levels. Conclusions: In general, considering the role of adipokines on metabolic disease and even chronic disease, this drug can be used as a potentially useful drug, especially in obese people, to improve these factors. © 2023 Elsevier B.V.